C

CrystalGenomics Inc
KOSDAQ:083790

Watchlist Manager
CrystalGenomics Inc
KOSDAQ:083790
Watchlist
Price: 1 329 KRW 3.83% Market Closed
Market Cap: 102.2B KRW

Net Margin

-274.2%
Current
Improving
by 153.8%
vs 3-y average of -428%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-274.2%
=
Net Income
₩-49.7B
/
Revenue
₩18.1B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-274.2%
=
Net Income
₩-49.7B
/
Revenue
₩18.1B

Peer Comparison

Country Company Market Cap Net
Margin
KR
CrystalGenomics Inc
KOSDAQ:083790
98.4B KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.7B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 96% of companies in Korea
Percentile
4rd
Based on 2 632 companies
4rd percentile
-274.2%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

CrystalGenomics Inc
Glance View

Market Cap
102.2B KRW
Industry
Biotechnology

CrystalGenomics, Inc. engages in the discovery and development of novel therapeutics. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2006-01-06. The firm operates its business through four segments. The Drug Substance Manufacturing segment manufactures and sells drug substances such as anti-inflammatory analgesics, antispasmodics, and asthma treatments. The Finished Drug Manufacturing segment produces and supplies finished drugs such as cephalosporin antibiotics. The Pharmaceutical Research and Development segment is engaged in the provision of clinical trial analysis and technical services, and sales of new drugs. The company also engages in real estate rental business. The Other segment is engaged in the manufacture and sale of hot pats and other household goods.

Intrinsic Value
Not Available
C
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-274.2%
=
Net Income
₩-49.7B
/
Revenue
₩18.1B
What is CrystalGenomics Inc's current Net Margin?

The current Net Margin for CrystalGenomics Inc is -274.2%, which is above its 3-year median of -428%.

How has Net Margin changed over time?

Over the last 3 years, CrystalGenomics Inc’s Net Margin has decreased from -64.6% to -274.2%. During this period, it reached a low of -1 002.8% on Dec 31, 2023 and a high of -64.6% on Aug 30, 2022.

Back to Top